Abstract
Platelets are known to play a fundamental role in acute coronary syndromes. After atherosclerotic plaque rupture, platelets can form pathogenic, occlusive thrombi leading to acute ischemic events. Today there are promising results from recently developed antiplatelet agents. However, morbidity and mortality from acute coronary syndromes remain significant despite the administration of combination therapies (aspirin, thienopyridines). Sharing similar mechanisms, platelets may also form a thin monolayer in areas of damaged endothelium contributing to primary hemostasis. For this reason, administration of antiplatelet drugs is often associated with increased bleeding risk. As a result, currently available antiplatelet therapy cannot be characterized as optimal. The precise mechanisms of platelet activation in acute coronary syndromes are still under investigation. The study of basic mechanisms of platelet adhesion, activation and aggregation after atherosclerotic plaque rupture may help to define new targets for their inhibition. In the future, newer antiplatelet agents may offer more comprehensive platelet inhibition without interfering with primary hemostasis, thus offering greater protection with lower hemorrhagic risk.
Keywords: Activation, acute coronary syndromes, adhesion, aggregation, antiplatelet agents, platelet, receptors, thrombosis, aspirin, thienopyridines
Current Vascular Pharmacology
Title:Mechanisms of Platelet Activation in Acute Coronary Syndromes
Volume: 10 Issue: 5
Author(s): Dimitrios A. Stakos, Dimitrios N. Tziakas and Konstantinos Stellos
Affiliation:
Keywords: Activation, acute coronary syndromes, adhesion, aggregation, antiplatelet agents, platelet, receptors, thrombosis, aspirin, thienopyridines
Abstract: Platelets are known to play a fundamental role in acute coronary syndromes. After atherosclerotic plaque rupture, platelets can form pathogenic, occlusive thrombi leading to acute ischemic events. Today there are promising results from recently developed antiplatelet agents. However, morbidity and mortality from acute coronary syndromes remain significant despite the administration of combination therapies (aspirin, thienopyridines). Sharing similar mechanisms, platelets may also form a thin monolayer in areas of damaged endothelium contributing to primary hemostasis. For this reason, administration of antiplatelet drugs is often associated with increased bleeding risk. As a result, currently available antiplatelet therapy cannot be characterized as optimal. The precise mechanisms of platelet activation in acute coronary syndromes are still under investigation. The study of basic mechanisms of platelet adhesion, activation and aggregation after atherosclerotic plaque rupture may help to define new targets for their inhibition. In the future, newer antiplatelet agents may offer more comprehensive platelet inhibition without interfering with primary hemostasis, thus offering greater protection with lower hemorrhagic risk.
Export Options
About this article
Cite this article as:
A. Stakos Dimitrios, N. Tziakas Dimitrios and Stellos Konstantinos, Mechanisms of Platelet Activation in Acute Coronary Syndromes, Current Vascular Pharmacology 2012; 10 (5) . https://dx.doi.org/10.2174/157016112801784477
DOI https://dx.doi.org/10.2174/157016112801784477 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Does Caffeine Affect Cardiovascular Responses?
Vascular Disease Prevention (Discontinued) An Overview of Published Papers and Important Developments in the Past Three Years
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Sepsis-induced Cardiomyopathy
Current Cardiology Reviews Role of the Endocannabinoid System in the Neuroendocrine Responses to Inflammation
Current Pharmaceutical Design Physiological and Pathophysiological Roles of ATP-Sensitive K+ Channels in Vascular Smooth Muscle
Vascular Disease Prevention (Discontinued) The Saphenous Vein as a Bypass Conduit: The Potential Role of Vascular Nerves in Graft Performance
Current Vascular Pharmacology Editorial
Current Medical Imaging The Role of T and B Cells in Atherosclerosis: Potential Clinical Implications
Current Pharmaceutical Design Recent Advances in the Discovery and Development of Direct Coagulation Factor Xa Inhibitors
Current Pharmaceutical Design Mesenchymal Stem Cells: A Good Candidate for Restenosis Therapy?
Current Vascular Pharmacology Contraindications for Anticoagulation in Older Patients with Atrial Fibrillation: A Narrative Review
Current Drug Safety What is the Role for Glycoprotein IIB/IIIA Inhibitor Use in the Catheterization Laboratory in the Current Era?
Current Vascular Pharmacology Pathophysiology of Idiopathic Atrial Fibrillation - Prognostic and Treatment Implications
Current Pharmaceutical Design Nanocarriers Assisted siRNA Gene Therapy for the Management of Cardiovascular Disorders
Current Pharmaceutical Design AMP-Activated Protein Kinase and Type 2 Diabetes
Current Medicinal Chemistry Pharmacological Neuroprotection in Stroke: Rationale, State-of-the-art and Future Directions
Current Neuropharmacology Innate Inflammatory Responses in Stroke: Mechanisms and Potential Therapeutic Targets
Current Medicinal Chemistry A Critical and Comprehensive Insight on Heme Oxygenase and Related Products Including Carbon Monoxide, Bilirubin, Biliverdin and Ferritin in Type-1 and Type-2 Diabetes
Current Pharmaceutical Design Metabolomics by Imaging; Biochemical-Magnetic Resonance Correlation: What We Learn from Combined Data of Magnetic Resonance Spectroscopy, NMR Spectroscopy, Clinical Chemistry and Tissue Content Analysis? Major Bottlenecks in Diagnosis
Recent Patents on Medical Imaging A2A Adenosine Receptor Agonists and their Potential Therapeutic Applications. An Update
Current Medicinal Chemistry